Emergent BioSolutions Inc. — Director's Dealing 2020

Feb 20, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2020-02-14

Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-14	Common Stock	M	4386	$25.62	Acquired	1483404	Direct
2020-02-14	Common Stock	S	4386	$63.90	Disposed	1479018	Direct
2020-02-18	Common Stock	M	15614	$25.62	Acquired	1494632	Direct
2020-02-18	Common Stock	S	15614	$63.90	Disposed	1479018	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-14	Employee Stock Options (Right to Buy)	$25.62	M	4386	Disposed	2021-03-10	Common Stock (4386)	Direct
2020-02-18	Employee Stock Options (Right to Buy)	$25.62	M	15614	Disposed	2021-03-10	Common Stock (15614)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4344250	Indirect
Common Stock	1524155	Indirect

Footnotes

F1: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934.

F2: Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.

F3: Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.

F4: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017.